| SC 13G/A | 2024-02-14 | LYTTON LAURENCE W | aTYR PHARMA INC | 585,013 | 1.0% | EDGAR |
| SC 13G/A | 2024-02-13 | Stonepine Capital Management, LLC | aTYR PHARMA INC | 482,258 | 0.8% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | aTYR PHARMA INC | 8,784,009 | 15.0% | EDGAR |
| SC 13G/A | 2024-01-18 | FEDERATED HERMES, INC. | aTYR PHARMA INC | 10,169,600 | 17.4% | EDGAR |
| SC 13G | 2024-01-02 | Logos Global Management LP | aTYR PHARMA INC | 5,800,000 | 9.9% | EDGAR |
| SC 13G | 2023-02-22 | LYTTON LAURENCE W | aTYR PHARMA INC | 4,440,188 | 8.7% | EDGAR |
| SC 13G/A | 2023-02-17 | Stonepine Capital Management, LLC | aTYR PHARMA INC | 4,569,433 | 8.9% | EDGAR |
| SC 13G/A | 2023-02-14 | Venrock Healthcare Capital Partners II, L.P. | aTYR PHARMA INC | 1,171,436 | 4.0% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | aTYR PHARMA INC | 4,351,407 | 15.0% | EDGAR |
| SC 13G/A | 2023-02-01 | FEDERATED HERMES, INC. | aTYR PHARMA INC | 5,231,600 | 18.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Venrock Healthcare Capital Partners II, L.P. | aTYR PHARMA INC | 1,565,000 | 5.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Alyeska Investment Group, L.P. | aTYR PHARMA INC | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Ikarian Capital, LLC | aTYR PHARMA INC | 35,048 | 0.1% | EDGAR |
| SC 13G/A | 2022-02-14 | TANG CAPITAL PARTNERS LP | aTYR PHARMA INC | 1,113,453 | 4.0% | EDGAR |
| SC 13G/A | 2022-02-14 | FEDERATED HERMES, INC. | aTYR PHARMA INC | 5,222,250 | 18.8% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | aTYR PHARMA INC | 4,168,601 | 15.0% | EDGAR |
| SC 13G/A | 2021-10-08 | FEDERATED HERMES, INC. | aTYR PHARMA INC | 5,222,250 | 19.9% | EDGAR |
| SC 13G | 2021-09-27 | Venrock Healthcare Capital Partners II, L.P. | aTYR PHARMA INC | 1,815,000 | 6.7% | EDGAR |
| SC 13G | 2021-09-17 | Ikarian Capital, LLC | aTYR PHARMA INC | 888,580 | 5.3% | EDGAR |
| SC 13G | 2021-09-17 | TANG CAPITAL PARTNERS LP | aTYR PHARMA INC | 1,063,453 | 6.3% | EDGAR |